Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2010

View Archived Issues

Several phase II/III trials show safety and efficacy of fingolimod in relapsing-remitting MS

Ganglioside vaccine NeuGcGM3/VSSP shows promise in melanoma

MEDI-8662 and CAIV-T flu vaccines demonstrate comparable safety/immunogenicity in phase III trial

FDA accepts for review GSK's response regarding Horizant in restless legs syndrome

Array Biopharma discloses promising preclinical data on ARRY-575

Pentraxin-3 has therapeutic activity in mice with P. aeruginosa lung infection

PCI-45292 more potent than PCI-32765 in arthritis models

Biocartis and bioMerieux partner to develop molecular diagnostics

Prana Biotechnology plans to conduct phase IIb PBT-2 trial in Alzheimer's disease

EVP-6124 enhances cognition as coagonist with acetylcholine

Boehringer Ingelheim claims new chemokine CCR3 receptor antagonists

FDA supports Pozen's design of phase III PA-32540 trial

Merck Serono discovers new DHOdehase inhibitors

New allosteric modulators of metabotropic glutamate mGlu1 receptor claimed

Ardea Biosciences reports data on RDEA-594 in gout

Pfizer presents novel mineralocorticoid receptor antagonists

Aeterna Zentaris identifies new quinaxoline derivatives for cancer therapy

Lilly to acquire Avid Radiopharmaceuticals

Raptor Pharma begins phase II DR cysteamine trial in Huntington's disease

StemCells to receive U.S. government grants to support stem cell projects

Genta begins phase IIb tesetaxel trial in metastatic breast cancer

Clinuvel receives FDA guidance on Scenesse program in erythropoietic protoporphyria

FDA approves IND for phase I/II development of RetinoStat in wet AMD

Results reported from phase III BLOOM-DM weight loss study in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...